AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie deferred Tax Assets, Net of Valuation Allowance [year-end] ($M) ($M)
Form 10-K Note 14 Income Taxes
Latest, FY2025
6,197
Period ended Dec 31, 2025
Change on a year earlier
+2.7%
6,036 in FY2024
History
11 years
Since FY2015
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred Tax Assets, Net of Valuation Allowance [year-end] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,197 | +2.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 6,036 | -6.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 6,458 | +16.7% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 5,532 | +6.6% | Form 10-K (filed 2024-02-20) ↗ |
| FY2021 | Dec 31, 2021 | 5,188 | -3.2% | Form 10-K (filed 2023-02-17) ↗ |
| FY2020 | Dec 31, 2020 | 5,359 | +92.4% | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 2,786 | +4.7% | Form 10-K (filed 2021-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 2,662 | +38.4% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 1,924 | -18.9% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 2,371 | +0.1% | Form 10-K (filed 2018-02-16) ↗ |
| FY2015 | Dec 31, 2015 | 2,369 | – | Form 10-K (filed 2017-02-17) ↗ |
Breakdown
What makes up deferred tax assets, net of valuation allowance [year-end] ($m)
- Deferred Tax Assets, Gross ($M)21,215 · FY2025
- Deferred Tax Assets Valuation Allowance ($M)15,000 · FY2025
- DTA — Net Operating Loss and Tax Credit Carryforwards ($M)16,022 · FY2025
- DTA — Chargebacks and Rebates ($M)1,482 · FY2025
- DTA — Other Accruals and Reserves ($M)1,133 · FY2025
- DTA — Compensation and Employee Benefits ($M)74 · FY2025
- DTA — Other ($M)2,504 · FY2025
- DTL — Intangible Assets ($M)1,530 · FY2025
- DTL — Excess Tax Basis in Investments ($M)322 · FY2025
- DTL — Other ($M)630 · FY2025
- Net Deferred Tax Liabilities ($M)3,715 · FY2025
Cite this data
StockData. (2026). AbbVie Deferred Tax Assets, Net of Valuation Allowance [year-end] ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/dta_net_tot
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.